885675-66-1

Basic information

• Product Name: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE
• Synonyms: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE;Thieno[3,2-d]pyriMidine, 2-chloro-6-[[4-(Methylsulfonyl)-1-piperazinyl]Methyl]-4-(4-Morpholinyl)-;4-(2-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)-methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine;2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE-8;2-chloro-6-((4-methanesulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine;4-(2-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)-methyl)thieno[3,2-d]pyrimidin-4-yl)morpholin
• CAS NO: 885675-66-1
• Molecular Formula: C₁₆H₂₂ClN₅O₃S₂
• Molecular Weight: 431.96058
• Mol File: 885675-66-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE(885675-66-1)
• EPA Substance Registry System: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE(885675-66-1)

Safety Data

• Hazardous Substances Data: 885675-66-1(Hazardous Substances Data)

Usage

General Description

2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE is a chemical compound that contains a thiophene ring fused to a pyrimidine ring, with a chloro substitution at the 2-position and a piperazine moiety with a methanesulfonyl group at the 6-position. It also contains a morpholine ring at the 4-position. 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE is of interest in medicinal chemistry and drug discovery due to its potential biological activities, such as anticancer or antiviral properties. It may be used as a starting point for the development of novel pharmaceutical agents targeting specific disease pathways.

Upstream product

• 164331-38-8 tert-butyl 4-(methylsulfonyl)piperazine-1-carboxylate 
• 1416327-30-4 1-((4-(methylsulfonyl)piperazin-1-yl)methyl)-1H-benzotriazole 
• 16234-15-4 2-chloro-4-morpholinothieno[3,2-d]pyrimidine 
• 885698-97-5 2-chloro-4-morpholinylthiophene[3,2-d]pyrimidine-6-methanol 
• 55276-43-2 4-methanesulfonylpiperazine 
• 1381841-06-0 4-(2-chloro-6-(chloromethyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 885618-31-5 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 
• 149-73-5 trimethyl orthoformate 
• 161357-89-7 1-(methylsulfonyl)piperazine hydrochloride 

Downstream Products

• 957054-30-7 pictilisib 
• 1381841-08-2 C₂₆H₃₃N₇O₄S₂ 
• 1381841-09-3 C₂₇H₃₅N₇O₄S₂ 
• 1381841-10-6 C₂₇H₃₅N₇O₄S₂ 
• 1381841-11-7 C₂₇H₃₇N₇O₄S₂ 
• 1381841-12-8 C₃₁H₄₅N₇O₄S₂ 
• 1381841-15-1 C₂₃H₂₈ClN₇O₄S₂ 
• 1381841-16-2 C₂₃H₂₇Br₂N₇O₄S₂ 
• 1146955-36-3 4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 957054-50-1 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)-morpholine bis-methanesulfonate 
• 1394047-75-6 (E)-4-(2-(2-((1-(3-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)methylene) hydrazinyl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1394047-74-5 (E)-4-(2-(2-((1-(4-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)methylene)hydrazinyl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1394047-73-4 (E)-4-(2-(2-((1-benzyl-1H-benzo[d]imidazol-2-yl)methylene)hydrazinyl)-6-((4-(methylsulfonyl)piperazin-1-yl) methyl)-thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1394047-72-3 (E)-4-(2-(2-((1-(2-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)methylene)hydrazinyl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 

Relevant articles and documents

Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies

Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.